The proteome, or collection of proteoforms expressed in a biological system, is dynamic and
heterogeneous. As our appreciation for the complexity of the proteome has evolved, so have …

Accumulation of advanced glycation end products (AGEs) on biopolymers accompanies
cellular aging and drives poorly understood disease processes. Here, we studied how AGEs …

Small molecules can serve as leads for new therapeutics as well as powerful tools to
investigate biological processes. Understanding the interactions of these molecules …

The endoplasmic reticulum (ER) employs a diverse proteome landscape to orchestrate
many cellular functions, ranging from protein and lipid synthesis to calcium ion flux and inter …

Natural products perennially serve as prolific sources of drug leads and chemical probes,
fueling the development of numerous therapeutics. Despite their scarcity, natural products …

We present a framework for the analysis of multiplexed mass spectrometry proteomics data
that reduces estimation error when combining multiple isobaric batches. Variations in the …

Friedreich's ataxia (FA) is a debilitating, multisystemic disease caused by the depletion of
frataxin (FXN), a mitochondrial iron-sulfur (Fe-S) cluster biogenesis factor. To understand the …

Mammalian target of rapamycin (mTOR) senses changes in nutrient status and stimulates
the autophagic process to recycle amino acids. However, the impact of nutrient stress on …

Reversible modification of target proteins by ubiquitin and ubiquitin-like proteins (UBLs) is
widely used by eukaryotic cells to control protein fate and cell behaviour. UFM1 is a UBL that …

Mapping the ligandability or potential druggability of all proteins in the human proteome is a
central goal of mass spectrometry-based covalent chemoproteomics. Achieving this …